Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial
Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…READ MORE
Carcinoid and Neuroendocrine Tumors in the News!
Who is at risk for getting carcinoid or another neuroendocrine cancer? What are the signs and symptoms? We are very pleased to share a feature article from the April 27, 2014 edition of the New York Daily News, “Daily Checkup: Carcinoid Tumors Have a Variety…READ MORE
Discover Something New in Carcinoid Syndrome
For patients who suffer from carcinoid syndrome – with symptoms such as diarrhea, frequent bowel movements, abdominal pain, and flushing – that is not adequately controlled by their current somatostatin analog therapy, there is an opportunity to participate…READ MORE